Test Price
2,800 AED✅ Home Collection Available
AIP Gene Germline Mutation Analysis (NGS) in UAE – 2800 AED – Accredited Molecular Diagnostics
Executive Summary & Core Metrics
This next‑generation sequencing (NGS) test provides full‑gene analysis of the AIP locus for germline mutations linked to growth hormone‑secreting pituitary adenomas. With 99.9% analytical sensitivity and ISO‑accredited processing, it supports endocrine surgical planning, familial cascade screening, and long‑term surveillance protocols.
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑Accredited NGS Workflow.
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Daily 8 AM – 11 PM).
- ✓ Clinical Guidance: Telephonic Post‑Test Genetic Counselling & Result Interpretation.
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The assay uses targeted next‑generation sequencing to interrogate all coding exons, intron‑exon boundaries, and selected regulatory regions of the AIP gene. Bioinformatic pipelines detect single‑nucleotide variants, small insertions/deletions, and large copy‑number alterations with 99.9% analytical sensitivity. Clinical interpretation follows ACMG/AMP guidelines and is correlated with endocrine phenotype, imaging findings, and family pedigree.
| Feature | Our Test (NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% sensitivity for all mutation types | ~95% – may miss large deletions/duplications |
| Methodology | Full‑gene NGS with deletion/duplication analysis | Single‑exon amplification & capillary electrophoresis |
| Turnaround | 3–4 Weeks | 6–8 Weeks |
Physician Insight & Safety Protocols
“A germline AIP mutation inherently confers a lifelong predisposition to pituitary adenomas, yet clinical penetrance varies widely. A positive result mandates correlation with growth hormone/IGF‑1 levels, pituitary MRI, and a three‑generation family history. It empowers proactive surveillance rather than fatalism.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Advisory – Medication Continuity
Patients currently receiving somatostatin analogues, dopamine agonists, or growth hormone receptor antagonists must not alter or discontinue therapy without explicit instruction from their treating endocrinologist. This genetic test does not replace ongoing clinical management.
Safety Exclusion Criteria & Emergency Red Flags
- This test is not intended for acute diagnostic emergencies or suspected pituitary apoplexy.
- Exclusion: Inability to provide a documented clinical history or three‑generation pedigree chart.
- Immediate medical attention required if: sudden severe headache, sudden vision loss, or rapid neurological decline – proceed to the nearest emergency department.
Patient FAQ & Clinical Guidance
1. What does the AIP gene test detect?
This test identifies inherited (germline) mutations in the AIP gene that predispose to growth hormone‑secreting pituitary adenomas and familial isolated pituitary adenoma (FIPA) syndrome. Results guide endocrine surveillance, surgical timing, and cascade testing of at‑risk relatives.
2. How long does it take to get results?
Following sample collection, NGS sequencing, bioinformatic analysis, and clinical variant interpretation require 3 to 4 weeks. This timeline ensures rigorous quality control and adherence to ACMG standards.
3. Is insurance accepted for this genetic test?
Direct billing with major UAE insurers is available. Send your policy details via WhatsApp to +971 54 548 8731 for instant verification and prior‑authorization assistance.
4. Can I take this test if I have no symptoms?
Yes. The test is appropriate for asymptomatic individuals with a family history of pituitary adenoma or acromegaly. A pre‑test genetic counselling session is recommended to discuss implications for insurance, employment, and family planning.
5. What sample type is required and how is it collected?
A standard peripheral whole‑blood sample (5–10 mL in EDTA) is sufficient. Collection is performed via VIP Mobile Phlebotomy at your home or office between 8 AM and 11 PM daily, with temperature‑controlled transport to the laboratory.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This diagnostic service operates under DHA Facility License Number 1143 and adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient genomic data handling. Secure data transmission, encryption, and access‑control protocols are further governed by Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. All laboratory processes are ISO 9001:2015 certified and subject to regular DHA audit.
Clinical & Logistical Metadata
| Test Name | AIP Gene Germline Mutation Analysis (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (Peripheral Blood, EDTA) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection Available |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full Gene with Deletion/Duplication Analysis |
| ICD-10-CM Code | D35.2, Z15.09 |
| LOINC Code | 83349-5 |
| DHA Facility License & Laboratory Address | DHA License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians